We are live on ! Find out more
PVCT

PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT

Delisted

PVCT was delisted on the 13th of October, 2016.

Back to rankings

7 hedge funds and large institutions have $17.1K invested in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in 2025 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 7 → 7 (0)

25% less capital invested

Capital invested by funds: $22.9K → $17.1K (-$5.81K)

Holders
7
Holders Change
–
Holders Change %
0%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
HFBOT
1
Home Federal Bank of Tennessee
Tennessee
$7.5K – – –
WPA
2
Wealth Preservation Advisors
Tennessee
$3.9K – – –
AW
3
Atlas Wealth
Ohio
$1.92K – – –
ACM
4
Academy Capital Management
Texas
$1.5K – – –
LIA
5
LBMC Investment Advisors
Tennessee
$1.5K – – –
FS
6
Financial Symmetry
North Carolina
$763 – – –

PVCT Hedge Fund Activity: Q2 2025 in Review

7 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) for Q2 2025, worth a combined $17.1K — down 25% from $22.9K a quarter earlier.

Fund positioning in PVCT was balanced in Q2 2025: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 7 institutional investors held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) as of Q2 2025, unchanged from Q1 2025.
  • Funds reported $17.1K of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) stock for Q2 2025, down 25% quarter-over-quarter.
  • 0 funds opened new PROVECTUS BIOPHARMACEUTICALS, INC. (DE) positions in Q2 2025 and 0 closed out.

Based on aggregated 13F filings for Q2 2025.